SACT

PART 1: THE ONCOLOGY PHARMACIST'S ROLE AND BONE MARROW TOXICITY

Section 1: The Evolving Role of the Oncology Pharmacist

1.1. The Imperative for Specialised Pharmacy Care (Page 2):

  • Increased Complexity of Care:

    • Volume & Regimens: The number of SACT regimens has exploded, moving beyond traditional cytotoxic chemotherapy to include targeted therapies, immunotherapy, and complex combination protocols.

    • Specialisation: Therapies are increasingly mechanism-specific (e.g., TKIs, ICIs, ADCs, bispecific antibodies), requiring deep pharmacological knowledge for safe handling, administration, and toxicity management.

    • Survival Gains: Patients live longer with cancer as a chronic condition, leading to prolonged exposure to SACT and its cumulative toxicities, alongside age-related comorbidities.

  • Expanded Scope of Practice: The pharmacist's role transitions from dispensing to active clinical management.

  • Pharmacist-Led Clinics: A model where pharmacists independently manage follow-up care for stable patients on oral SACT or supportive therapies. They perform:

    • Toxicity assessment and management.

    • Adherence counselling.

    • Dose modifications based on protocols.

    • Patient education and psychosocial support.

    • Monitoring of long-term effects.

  • Impact: This model improves patient access, continuity of care, and frees up oncologist time for complex decision-making.

Section 2: Myelosuppression – The Most Common Dose-Limiting Toxicity

2.1. Bone Marrow Physiology and Chemotherapy Impact (Page 3-4):
Chemotherapy targets rapidly dividing cells. The bone marrow, with its high proliferative rate for hematopoiesis, is highly susceptible.

  • Neutropenia: Reduction in neutrophils (Absolute Neutrophil Count, ANC <1.5 x 10⁹/L). Grade 3/4 neutropenia (ANC <1.0 or <0.5 x 10⁹/L) is critical.

    • Consequence: Profoundly increased risk of bacterial and fungal infections. Fever in a neutropenic patient (Febrile Neutropenia) is a medical emergency.

  • Anaemia: Reduction in haemoglobin.

    • Consequence: Fatigue, dyspnoea, pallor, reduced quality of life. Managed with red blood cell transfusions for symptomatic relief. Erythropoiesis-stimulating agents (ESAs) are used cautiously due to thromboembolic risk and potential tumour progression concerns.

  • Thrombocytopenia: Reduction in platelets (<100 x 10⁹/L).

    • Consequence: Risk of bleeding (petechiae, bruising, mucosal bleeding). Managed with platelet transfusions for active bleeding or very low counts (<10 x 10⁹/L).

2.2. The Concept of Nadir (Page 5):

  • Definition: The lowest point of blood cell counts following a cycle of chemotherapy.

  • Timing: Typically occurs 7-14 days post-administration for most cytotoxic drugs (varies by agent).

  • Clinical Application: Knowing the nadir timing informs monitoring schedules and patient counselling about the highest risk period for infection and bleeding.

2.3. Patient Counselling for Neutropenia (Page 6):
A comprehensive list of behavioural modifications to minimise infection risk:

  • Hand Hygiene: For patient and all visitors.

  • Avoid Crowds/Masks: In public places.

  • Avoid Sick Contacts: Including children (specifically avoid changing nappies due to high pathogen load).

  • Avoid Environmental Risks: Swimming pools (Pseudomonas risk), fresh flowers/potted plants (Aspergillus in soil), bird/reptile droppings.

  • Pet Care: Avoid cleaning litter boxes/ cages; careful handwashing after contact.

2.4. Clinical Challenge: Febrile Neutropenia (Page 7):

  • Scenario: Patient 8 days post-chemotherapy (within nadir window) presents with fever.

  • Urgent Action Required: This is a potential oncologic emergency. The patient must be instructed to go to hospital immediately (A&E) for assessment. They require:

    • Broad-spectrum IV antibiotics (e.g., piperacillin-tazobactam) within 1 hour of presentation.

    • Full septic work-up (blood cultures, CXR).

    • Possible admission for neutropenic sepsis management.

  • Key Learning: Patients must be educated pre-emptively to check temperature and seek immediate help for fever ≥38°C during the at-risk period.

PART 2: GASTROINTESTINAL TOXICITIES

Section 3: Chemotherapy-Induced Nausea and Vomiting (CINV)

3.1. Emetogenic Potential Classification (Page 8):
Drugs are categorised by the frequency of causing emesis without prophylaxis:

  • High (>90%): Cisplatin (the archetype), AC regimen (Doxorubicin + Cyclophosphamide for breast cancer).

  • Moderate (30-90%): Carboplatin, Doxorubicin, Oxaliplatin, Cyclophosphamide (<1500 mg/m²).

  • Low (10-30%): Docetaxel, Paclitaxel, Etoposide.

  • Minimal (<10%): Bevacizumab, Vincristine, targeted therapies (TKIs), immunotherapy (usually).

3.2. Pathophysiology and Mediators (Page 9):
CINV is triggered via multiple pathways, targeting receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract:

  • Serotonin (5-HT₃): Released from enterochromaffin cells in the gut after cytotoxic damage; activates vagal afferents. Key for acute CINV.

  • Substance P (NK₁): Acts centrally in the vomiting centre. Key for delayed CINV.

  • Dopamine (D₂): Classical pathway, targeted by older antiemetics.

  • Histamine (H₁), Acetylcholine (Muscarinic): Involved in motion sickness and general emesis.

3.3. Contributing Factors (Page 11):
Beyond the chemotherapy drug itself:

  • Drug-Induced: Opioids, antibiotics.

  • Disease-Induced: Brain metastases, bowel obstruction, hypercalcaemia.

  • Metabolic: Renal failure (accumulation of emetogenic toxins).

  • Psychological: Anxiety, anticipatory nausea (a conditioned response).

  • GI: Constipation.

3.4. Antiemetic Agents by Class (Page 12):

  • 5-HT₃ Antagonists (e.g., Ondansetron, Granisetron): First-line for acute CINV. Block peripheral and central 5-HT₃ receptors.

  • NK₁ Antagonists (e.g., Aprepitant, Fosaprepitant, Rolapitant): Critical for preventing delayed CINV. Often used in combination for high/moderate risk regimens.

  • Corticosteroids (e.g., Dexamethasone): Potent anti-inflammatory and antiemetic; cornerstone of combination prophylaxis. Used for both acute and delayed phases.

  • Dopamine Antagonists:

    • Metoclopramide: Prokinetic and D₂ antagonist; used for breakthrough or delayed nausea.

    • Olanzapine (Atypical Antipsychotic): Blocks multiple receptors (D₂, 5-HT₂); highly effective for breakthrough and refractory CINV.

  • Antihistamines (e.g., Cyclizine): Useful for nausea with a vertiginous component.

  • Benzodiazepines (e.g., Lorazepam): For anticipatory nausea, due to anxiolytic and amnesic effects.

3.5. Types and Management of CINV (Page 13):

  • Acute: Occurs within 0-24 hours of chemotherapy. Managed with combination prophylaxis (e.g., 5-HT₃ antagonist + Dexamethasone + NK₁ antagonist for high risk).

  • Delayed: Occurs 24 hours to 5 days post-chemotherapy. Managed with Dexamethasone + NK₁ antagonist (e.g., Aprepitant for 3 days).

  • Anticipatory: A conditioned response before chemotherapy. Managed with behavioural techniques and Lorazepam.

  • Breakthrough: Nausea/vomiting despite prophylaxis. Requires rescue medications (e.g., Olanzapine, Metoclopramide).

3.6. Prophylaxis is Key (Page 14):

  • Timing: Antiemetics should be given 30 minutes before chemotherapy and continued at home for 2-3 days as prescribed to cover the delayed phase.

  • Clinical Challenge (Page 15): For highly emetogenic chemotherapy (HEC) like cisplatin, the recommended regimen is a triple therapy: 5-HT₃ antagonist (Day 1) + Dexamethasone (Days 1-4) + NK₁ antagonist (Days 1-3). Olanzapine may be added for even greater protection.

Section 4: Other GI Toxicities

4.1. Diarrhoea (Page 16):

  • High-Risk Agents:

    • Fluoropyrimidines (5-FU, Capecitabine): Cause direct mucosal damage.

    • Irinotecan: Causes biphasic diarrhoea.

      • Acute, Early-Onset (within 24 hrs): Caused by an acetylcholine surge. Prevented/treated with atropine.

      • Delayed (≥24 hrs later): Caused by damaged intestinal mucosa and secretory diarrhoea. Managed aggressively with high-dose loperamide (e.g., 4 mg stat, then 2 mg every 2 hours until 12 hours stool-free). Severe cases may require hospitalisation for IV fluids and octreotide.

  • Management: Fluid/electrolyte replacement, antimotility agents (loperamide), and dose reductions.

4.2. Constipation (Page 17):

  • Common Culprits: Opioids (for pain management) and Vinca alkaloids (e.g., Vincristine – causes autonomic neuropathy).

  • Management: Prophylactic laxatives are mandatory when starting opioids (e.g., combination stimulant + softener like senna + docusate). Treatment may require osmotic laxatives (lactulose, polyethylene glycol) or enemas.

4.3. Mucositis/Stomatitis (Page 18):

  • Pathogenesis: Cytotoxic damage to the rapidly dividing epithelial lining of the entire GI tract, most visibly in the oral cavity.

  • High-Risk Agents: 5-FU, Methotrexate, Anthracyclines.

  • Prevention & Management:

    • Oral Cryotherapy (Ice Chips): For short-infusion agents like 5-FU. Vasoconstriction reduces drug delivery to oral mucosa. Caution with Oxaliplatin (can exacerbate cold-induced neuropathy).

    • Good Oral Hygiene: Soft toothbrush, saline/sodium bicarbonate rinses to prevent superinfection.

    • "Mouthwash Cocktail": Often a compounded mixture containing agents like lidocaine (anaesthetic), diphenhydramine (antihistamine/coating), nystatin (antifungal), and a steroid or antacid. Used for symptomatic relief of pain and inflammation.

PART 3: ORGAN-SPECIFIC TOXICITIES

Section 5: Renal Toxicity

5.1. Cisplatin Nephrotoxicity (Pages 19-20):

  • Incidence & Severity: Dose-limiting toxicity for cisplatin, occurring in 25-40% of patients. Can be irreversible.

  • Mechanism: Cisplatin is concentrated in renal tubular cells. It forms intra-strand and inter-strand DNA cross-links, causing tubular cell apoptosis and necrosis. This alters tubular secretion/absorption, leading to wasting of electrolytes (Mg²⁺, K⁺, Ca²⁺) and a decline in glomerular filtration rate (increased serum creatinine).

  • Prevention is Paramount:

    • Aggressive Hydration: Pre-, during, and post-infusion with normal saline to maintain high urine output (>100 mL/hr), diluting cisplatin concentration in tubules.

    • Mannitol/Osmotic Diuresis: Sometimes used to force diuresis.

    • Electrolyte Monitoring & Replacement: Particularly Magnesium, which is almost universally depleted.

5.2. Ifosfamide & Hemorrhagic Cystitis (Page 21):

  • Mechanism: Ifosfamide metabolite acrolein is directly toxic to the bladder urothelium, causing inflammation, ulceration, and haemorrhage.

  • Prevention: Mesna (sodium 2-mercaptoethanesulfonate). Mesna binds to and neutralizes acrolein in the urine. It is given IV or orally around the time of ifosfamide infusion.

  • Additional Measure: Hyperhydration to dilute urinary acrolein concentration.

Section 6: Neurotoxicity

6.1. Peripheral Neuropathy (Page 22):

  • Mechanism: Damage to sensory (and sometimes motor) axons. Often due to microtubule disruption or impaired DNA/RNA synthesis in neurons.

  • High-Risk Agents:

    • Platinum Agents (Cisplatin, Oxaliplatin): Cumulative, dose-dependent. Cisplatin target: ~300 mg/m² cumulative dose. Oxaliplatin causes acute cold-induced and chronic neuropathy.

    • Taxanes (Paclitaxel, Docetaxel): Microtubule stabilisation disrupts axonal transport.

    • Vinca Alkaloids (Vincristine): Microtubule disruption.

  • Symptoms: Paraesthesia (tingling, numbness), pain, loss of proprioception (balance issues), loss of fine motor skills. Typically starts in fingers/toes ("glove and stocking" distribution) and progresses proximally.

  • Management: Dose reduction/delay is often required. Symptomatic treatments (e.g., duloxetine, gabapentin) have modest benefit. Prevention strategies (e.g., cryotherapy for hands/feet during paclitaxel) are being studied.

6.2. Central Neurotoxicity (Page 23):

  • Cytarabine (ARA-C) – Cerebellar Syndrome:

    • Risk with High-Dose (>1 g/m²): Cytarabine or its metabolite accumulates in the cerebellum, damaging Purkinje cells.

    • Symptoms: Cerebellar ataxia (unsteady gait, clumsiness), dysarthria (slurred speech), nystagmus. Assess with finger-nose test, heel-shin test, and handwriting assessment.

    • Management: Drug discontinuation; toxicity may be irreversible.

  • Intrathecal Methotrexate – Chemical Meningitis:

    • Mechanism: Direct chemical irritation of the meninges.

    • Symptoms: Headache, nausea, vomiting, neck stiffness, fever.

    • Management/Prevention: Corticosteroids (e.g., dexamethasone) co-administered intrathecally or systemically can reduce incidence.

Section 7: Hepatotoxicity, Dermatological, and Local Toxicity

7.1. Hepatotoxicity (Page 24):

  • Mechanism: Can be direct hepatocellular injury, cholestatic, or mixed. The liver is the primary site of metabolism for many drugs.

  • High-Risk Agents: Anthracyclines (metabolised in liver), Methotrexate (can cause fibrosis), TKIs, ICIs (immune-mediated hepatitis).

  • Monitoring: Liver function tests (LFTs: ALT, AST, ALP, Bilirubin). Dose adjustments or holds are required for elevated bilirubin with drugs like doxorubicin.

7.2. Palmar-Plantar Erythrodysesthesia (PPE) / Hand-Foot Syndrome (Page 25):

  • Mechanism: Leakage of drug (e.g., Capecitabine, 5-FU, liposomal doxorubicin) from capillaries in high-friction areas of palms and soles, causing local tissue damage and inflammation.

  • Symptoms: Painful erythema, swelling, tingling, blistering, desquamation (peeling).

  • Management: Dose reduction/interruption, supportive care (moisturisers, cooling, pain relief). Prophylactic pyridoxine (vitamin B6) is sometimes used with limited evidence.

7.3. Extravasation (Page 26):

  • Definition: Leakage of a vesicant or irritant chemotherapeutic agent from the vein into the surrounding subcutaneous tissue.

  • Vesicants: Cause severe tissue damage, necrosis, and ulceration (e.g., Anthracyclines - Doxorubicin, Vinca alkaloids - Vincristine).

  • Irritants: Cause pain, inflammation, and phlebitis but not necrosis (e.g., Taxanes).

  • Prevention: Use of central venous lines (e.g., PICC, Port-a-Cath), careful peripheral IV site selection, monitoring during infusion.

  • Management (Vesicant):

    • Immediate: Stop infusion, aspirate residual drug from line, DO NOT FLUSH. Apply cold pack for anthracyclines (vasoconstriction); warm pack for vinca alkaloids (vasodilation, disperse).

    • Specific Antidotes:

      • Dexrazoxane for anthracycline extravasation.

      • Hyaluronidase for vinca alkaloids, taxanes (facilitates diffusion and dilution).

    • Surgical Consultation: For severe cases with impending necrosis.

7.4. Ocular Toxicity (Page 27):

  • Targeted Therapies (e.g., EGFR inhibitors): Cause keratitis, dry eye, corneal perforation. Onset ~6 weeks. Requires ophthalmology monitoring.

  • High-Dose Cytarabine: Causes chemical conjunctivitis. Due to low levels of cytidine deaminase (the metabolising enzyme) in the eye.

  • Prevention: Prophylactic steroid eye drops (e.g., dexamethasone ophthalmic) throughout treatment and for 2 days after.

7.5. Ototoxicity (Page 28):

  • Agent: Cisplatin accumulates in the cochlea, damaging outer hair cells and the stria vascularis.

  • Effect: High-frequency sensorineural hearing loss, often permanent and bilateral. Can also cause tinnitus.

  • Management: Baseline audiogram before treatment and monitoring during therapy. Dose adjustments may be needed. Patient counselling (e.g., difficulty with phone conversations).

PART 4: IMMUNE-RELATED ADVERSE EVENTS (irAEs) AND CARDIO-ONCOLOGY

Section 8: Immune Checkpoint Inhibitors (ICIs) and irAEs

8.1. Fundamental Mechanism of ICIs and irAEs (Pages 29-32):

  • Immune Checkpoints: Normal "brakes" (e.g., CTLA-4, PD-1/PD-L1) that prevent autoimmunity by downregulating T-cell activity.

  • ICI Action: Monoclonal antibodies block these checkpoints, releasing the brakes and allowing T-cells to attack cancer.

  • The Double-Edged Sword: The same activated T-cells can mistakenly attack healthy tissues, causing immune-related adverse events (irAEs).

  • Key Difference from Chemotoxicity (Page 31 Table):

    • Onset: Can occur any time, even months after stopping treatment.

    • Type: Autoimmune/inflammatory (colitis, hepatitis, pneumonitis, endocrinopathies, rash) rather than cytotoxic (alopecia, mucositis).

    • Management: Immunosuppression with corticosteroids, not just supportive care.

8.2. Spectrum of irAEs (Page 32):

  • Skin (Most Common): Maculopapular rash, pruritus, vitiligo.

  • Gastrointestinal: Colitis (diarrhoea, abdominal pain) – one of the most common serious irAEs.

  • Endocrine: Hypothyroidism (common), hypophysitis (pituitary inflammation), adrenal insufficiency, type 1 diabetes.

  • Pulmonary: Pneumonitis (cough, dyspnoea) – can be life-threatening.

  • Hepatitis: Elevated LFTs.

  • Nephritis: Elevated creatinine.

  • Cardiac: Myocarditis (rare but highly fatal).

  • Neurological: Neuropathy, myasthenia gravis-like syndrome.

8.3. Management Principles for irAEs (Pages 33-34):

  • Grading is Crucial: Based on Common Terminology Criteria for Adverse Events (CTCAE).

    • Grade 1 (Mild): Continue ICI, monitor, symptomatic care.

    • Grade 2 (Moderate): Hold ICI. Start prednisone 0.5-1 mg/kg/day. Taper over ≥4 weeks once improved to Grade 1.

    • Grade 3-4 (Severe/Hospitalisation): Permanently discontinue ICI. Start IV methylprednisolone 1-2 mg/kg/day. If no improvement in 48-72 hrs, add second-line immunosuppressant (e.g., infliximab for colitis, mycophenolate for hepatitis).

  • Special Case – Endocrine irAEs: Often require lifelong hormone replacement (e.g., levothyroxine for hypothyroidism) but do not typically require permanent ICI discontinuation.

  • Patient Education (Page 34): Patients must be empowered to report ANY new symptom, no matter how minor. They must understand steroid tapering plans to avoid adrenal crisis.

8.4. Long-Term Monitoring (Page 35):

  • IrAEs can be delayed or chronic. Survivorship programmes must include lifelong vigilance for late-onset toxicities (e.g., late-onset diabetes, adrenal insufficiency).

  • Quality of Life (QoL): Assessing physical, emotional, and psychosocial well-being is integral, as chronic irAEs and fear of recurrence significantly impact QoL.

Section 9: Cardio-Oncology – A Critical Emerging Discipline

9.1. Definition and Rationale (Pages 37-39, 44-50):

  • Definition: A multidisciplinary field focused on the prevention, early detection, and management of cardiovascular disease in cancer patients and survivors.

  • The "Perfect Storm" Driving the Epidemic (Page 38):

    1. Ageing Population: Higher baseline CV risk.

    2. Improved Survival: More patients live long enough to experience late cardiotoxicity.

    3. Cardiotoxic Therapies: Many SACT agents directly damage the heart.

    4. Shared Risk Factors: Smoking, obesity, diabetes contribute to both cancer and CVD.

9.2. Specific Cardiotoxicities and Management (Pages 40-47):

A. Left Ventricular Dysfunction (LVD) / Heart Failure (Pages 40-41):

  • Type I (Anthracyclines - e.g., Doxorubicin): Dose-dependent, irreversible myocyte damage via oxidative stress. Cumulative lifetime dose limit (e.g., Doxorubicin ~450 mg/m²). Mechanism: Free radical generation, topoisomerase IIβ inhibition, mitochondrial dysfunction.

  • Type II (Trastuzumab): Not dose-dependent, often reversible upon drug cessation. Mechanism related to blocking HER2 signalling essential for cardiomyocyte repair. Risk exacerbated by prior anthracycline use.

  • Monitoring: Baseline and serial echocardiograms (or MUGA scans) to measure Left Ventricular Ejection Fraction (LVEF).

B. Arrhythmias (Page 44):

  • Atrial Fibrillation (AF): Common with ibrutinib, cisplatin, others.

  • QTc Prolongation (Page 45): Risk of Torsades de Pointes. Caused by many TKIs (vandetanib, sunitinib), arsenic trioxide, HDAC inhibitors.

    • Management: Baseline ECG, monitor electrolytes (K⁺, Mg²⁺), avoid concomitant QT-prolonging drugs, use Fridericia correction. Hold drug if QTc >500 ms or increase >60 ms from baseline.

C. Hypertension (Page 46):

  • Common with: VEGF/VEGFR inhibitors (e.g., bevacizumab, sunitinib, pazopanib). Mechanism involves reduced nitric oxide and endothelial dysfunction.

  • Management: Aggressive control (target <130/80 mmHg). Avoid CYP3A4 inhibitors like diltiazem/verapamil if patient is on TKIs metabolised by this pathway (e.g., sorafenib). Use ACEi/ARBs, dihydropyridine CCBs (e.g., amlodipine).

D. Ischaemia/Thrombosis (Page 47):

  • Agents: Fluoropyrimidines (5-FU, capecitabine) – can cause coronary vasospasm. Cisplatin, VEGF inhibitors – increase thrombotic risk.

  • Management: For 5-FU chest pain, stop infusion, consider nitrates/CCBs. Manage CV risk factors aggressively.

E. Drug Interactions (Page 48-49):

  • Critical in Cardio-Oncology: Cancer patients are on polypharmacy (SACT, antiemetics, analgesics, CV drugs).

  • Examples:

    • CYP3A4 Interactions: Many TKIs are CYP3A4 substrates. Co-administration with strong inhibitors (e.g., clarithromycin, azole antifungals) can increase TKI levels and toxicity. Inducers (e.g., phenytoin) can reduce efficacy.

    • QTc Prolongation Additivity.

    • Bleeding Risk: Anticoagulants/antiplatelets with myelosuppressive chemotherapy.

9.3. The ROYAL MARSDEN Real-World Study (Pages 51-61):

  • Objective: Investigate cardiotoxicity in NSCLC patients treated with TKIs or ICIs.

  • Key Findings:

    • Prevalence: 88/451 (19.5%) patients experienced cardiotoxicity.

    • Most Common Toxicities: Heart failure, arrhythmias, myocardial ischaemia.

    • Drugs Most Associated: Osimertinib (EGFR TKI) and Pembrolizumab (ICI).

    • Time to Onset: Median 5 months, but 30% occurred within the first month. Data was not normally distributed, emphasising unpredictable timing.

    • Risk Factors (Page 60): Significantly increased odds with:

      • Prior Cardiac History (OR 2.0)

      • Hypertension (OR 1.9)

      • Concurrent Cardiotoxic Drug (OR 2.1)

  • Take-Home Messages (Page 61):

    1. Baseline CV risk stratification is essential before starting SACT.

    2. Serial monitoring (echo, ECG, biomarkers) during and after treatment.

    3. Vigilance for drug-drug interactions.

9.4. Case Study: Patient GH (Pages 64-66):

  • Scenario: HER2+ breast cancer patient on anthracycline (epirubicin) followed by trastuzumab.

  • Clinical Course: Baseline low risk. After anthracycline, risk upgraded to medium. Serial echos initially stable, but after 11 cycles of HER2 therapy, significant LVEF drop (to 45-50%) was detected in an asymptomatic patient.

  • Management & Learning Points:

    • Asymptomatic Detection: Highlights the critical importance of routine imaging surveillance even in low-risk patients.

    • Cardio-Oncology Collaboration: Close teamwork allowed initiation of cardioprotective medications (Ramipril, Bisoprolol) without stopping life-saving trastuzumab.

    • Successful Outcome: LVEF improved with medical management, allowing completion of full 18-cycle trastuzumab course, maximizing oncologic outcome.

    • Key Message: "No room for complacency based on early monitoring." Toxicity can manifest late in the treatment course.

9.5. The Pharmacist's Role in Cardio-Oncology (Pages 50, 67):

  • Risk Stratification: Using tools like the ESC risk assessment algorithms.

  • Medication Review: Identifying and managing drug interactions, optimising CV medications.

  • Monitoring Coordination: Ensuring appropriate scheduling of cardiac tests.

  • Patient Education: On symptoms of cardiotoxicity (e.g., breathlessness, oedema, palpitations).

  • Interprofessional Collaboration: Early referral to cardio-oncology services, and collaboration with primary care for long-term management.

Summary: The Oncology Pharmacist as a Guardian of Safety

This comprehensive overview underscores that modern oncology pharmacy is about proactive toxicity prevention, vigilant monitoring, and sophisticated management across a vast spectrum of acute and chronic adverse events. From managing febrile neutropenia and CINV, to recognising life-threatening irAEs, to navigating the complex intersection of cancer therapy and cardiovascular health, the pharmacist is an indispensable member of the MDT, crucial for optimizing both the safety and efficacy of cancer care.


QUESTIONS:

Section 1: Single Best Answer (SBA) Questions

Q1:

A patient is scheduled to receive their first cycle of cisplatin for lung cancer. What is the single most important preventative measure to minimise the risk of nephrotoxicity?
a) Pre-treatment with intravenous Mesna
b) Aggressive intravenous hydration with normal saline before, during, and after the infusion
c) Concurrent administration of dexamethasone
d) Prophylactic use of loop diuretics like furosemide

Answer:

b) Aggressive intravenous hydration with normal saline before, during, and after the infusion
*Rationale: Cisplatin-induced nephrotoxicity is caused by concentrated drug in the renal tubules. Aggressive hydration (typically 1-2L pre- and post-infusion) dilutes the drug in the tubules and maintains a high urine output (>100 mL/hr), which is the cornerstone of prevention. Mesna is used for ifosfamide-induced cystitis, not cisplatin nephrotoxicity.*

Q2:

A patient on FOLFIRI (5-FU, leucovorin, irinotecan) for colorectal cancer develops profuse, watery diarrhoea starting 48 hours after their infusion. What is the most appropriate initial management?
a) Administer atropine 0.25-1 mg IV/SC
b) Start high-dose loperamide (e.g., 4 mg stat, then 2 mg every 2 hours until 12 hours stool-free)
c) Prescribe a course of oral metronidazole
d) Recommend a clear liquid diet and monitor

Answer:

b) Start high-dose loperamide (e.g., 4 mg stat, then 2 mg every 2 hours until 12 hours stool-free)
*Rationale: Diarrhoea starting >24 hours post-irinotecan is the delayed, secretory type caused by mucosal damage. This requires aggressive antimotility therapy with a high-dose loperamide regimen to prevent dehydration and electrolyte imbalance. Atropine is used for the acute, cholinergic diarrhoea that can occur during or immediately after irinotecan infusion.*

Q3:

Which of the following antiemetic regimens is the most appropriate for prophylaxis in a patient about to receive their first cycle of AC (doxorubicin + cyclophosphamide) chemotherapy for breast cancer?
a) Ondansetron 8 mg IV + Dexamethasone 8 mg IV on day 1 only
b) Ondansetron 8 mg IV + Dexamethasone 12 mg IV on day 1, followed by Dexamethasone 8 mg orally on days 2-4
c) Aprepitant 125 mg orally + Ondansetron 8 mg IV + Dexamethasone 12 mg IV on day 1, followed by Aprepitant 80 mg orally on days 2-3 and Dexamethasone 8 mg orally on days 2-4
d) Metoclopramide 10 mg orally three times daily for 5 days

Answer:

c) Aprepitant 125 mg orally + Ondansetron 8 mg IV + Dexamethasone 12 mg IV on day 1, followed by Aprepitant 80 mg orally on days 2-3 and Dexamethasone 8 mg orally on days 2-4
*Rationale: The AC regimen is highly emetogenic (>90% risk). Current guidelines recommend a three-drug regimen (NK1 antagonist + 5-HT3 antagonist + corticosteroid) for both acute and delayed phase protection. This combination covers the key pathways (NK1 for delayed, 5-HT3 for acute) and provides superior control.*

Q4:

A patient receiving pembrolizumab (an anti-PD-1 immunotherapy) presents with new-onset grade 2 colitis (diarrhoea 4-6 stools/day over baseline, abdominal pain). What is the recommended management?
a) Continue pembrolizumab, administer loperamide, and review in clinic in 1 week.
b) Permanently discontinue pembrolizumab and start infliximab immediately.
c) Hold pembrolizumab, start oral prednisone 1 mg/kg/day, and begin a slow taper over ≥4 weeks once symptoms improve.
d) Hospitalise for IV fluids and start IV methylprednisolone 2 mg/kg/day.

Answer:

c) Hold pembrolizumab, start oral prednisone 1 mg/kg/day, and begin a slow taper over ≥4 weeks once symptoms improve.
*Rationale: For moderate (Grade 2) immune-related adverse events (irAEs), the standard management is to temporarily hold the immune checkpoint inhibitor and initiate moderate-dose corticosteroids (0.5-1 mg/kg/day prednisone equivalent). The steroid must be tapered slowly over at least 4 weeks to avoid rebound inflammation. Permanent discontinuation and infliximab are reserved for severe (Grade 3-4) irAEs.*

Q5:

The primary mechanism of anthracycline (e.g., doxorubicin) cardiotoxicity is best described as:
a) Reversible inhibition of HER2 signalling in cardiomyocytes
b) Dose-dependent, irreversible myocardial damage due to oxidative stress and topoisomerase IIβ inhibition
c) Coronary vasospasm leading to myocardial ischaemia
d) QTc prolongation leading to Torsades de Pointes

Answer:

b) Dose-dependent, irreversible myocardial damage due to oxidative stress and topoisomerase IIβ inhibition
Rationale: Anthracyclines cause Type I cardiotoxicity. The iron-anthracycline complex generates free radicals, causing lipid peroxidation and direct damage to cardiomyocyte membranes and mitochondria. Inhibition of topoisomerase IIβ in the heart disrupts DNA repair. This damage is cumulative and often irreversible, leading to strict lifetime dose limits.

Q6:

Which agent is correctly paired with its specific preventive or antidotal therapy for a unique toxicity?
a) Cisplatin → Mesna for nephrotoxicity
b) Ifosfamide → Dexrazoxane for haemorrhagic cystitis
c) Anthracycline extravasation → Hyaluronidase
d) High-dose cytarabine → Prophylactic steroid eye drops

Answer:

d) High-dose cytarabine → Prophylactic steroid eye drops
*Rationale: High-dose cytarabine can cause chemical conjunctivitis. Prophylactic corticosteroid eye drops (e.g., dexamethasone 0.1%) are standard during and for 2 days after therapy to prevent this. Mesna is for ifosfamide cystitis. Dexrazoxane is for anthracycline extravasation. Hyaluronidase is for vinca alkaloid or taxane extravasation.*

Q7:

A patient on capecitabine reports painful redness, swelling, and peeling on the palms of their hands and soles of their feet. What is this toxicity, and what is the primary management strategy?
a) Extravasation injury; apply warm compresses and refer for surgical review.
b) Palmar-Plantar Erythrodysesthesia (PPE) / Hand-Foot Syndrome; interrupt therapy and provide supportive care (moisturisers, pain relief).
c) Immune-related dermatitis; start topical corticosteroids and continue capecitabine.
d) Peripheral neuropathy; initiate gabapentin and reduce the next dose.

Answer:

b) Palmar-Plantar Erythrodysesthesia (PPE) / Hand-Foot Syndrome; interrupt therapy and provide supportive care (moisturisers, pain relief).
*Rationale: This is a classic description of PPE, a common toxicity of fluoropyrimidines like capecitabine. It results from drug leakage in capillaries of high-friction areas. Management involves dose interruption/modification, cooling, analgesia, and emollients. Pyridoxine (B6) is sometimes used prophylactically with limited evidence.*

Q8:

A patient is 7 days post-cycle 1 of docetaxel for breast cancer. They call the clinic reporting a temperature of 38.5°C and feeling shivery. Their last blood count is unknown. What is the most appropriate immediate advice?
a) Take paracetamol 1g and call back if the fever persists in 4 hours.
b) Go immediately to the nearest Emergency Department.
c) Start a course of broad-spectrum oral antibiotics from their standby supply.
d) Attend their scheduled clinic appointment tomorrow.

Answer:

b) Go immediately to the nearest Emergency Department.
*Rationale: Fever during the expected nadir period (7-14 days post-cytotoxic chemotherapy) is a potential sign of febrile neutropenia, an oncologic emergency. These patients require immediate hospital assessment, blood cultures, and administration of empiric broad-spectrum IV antibiotics within 1 hour to prevent progression to septic shock. Delaying treatment can be fatal.*

Q9:

Which of the following best describes the mechanism of action of olanzapine when used for breakthrough chemotherapy-induced nausea and vomiting (CINV)?
a) Pure 5-HT3 receptor antagonism
b) Pure dopamine D2 receptor antagonism
c) Blockade of multiple receptors including dopamine, serotonin, and histamine
d) Inhibition of substance P binding to the NK1 receptor

Answer:

c) Blockade of multiple receptors including dopamine, serotonin, and histamine
*Rationale: Olanzapine is an atypical antipsychotic with broad receptor antagonism (D1, D2, D4, 5-HT2A, 5-HT2C, 5-HT3, H1). This multi-target action makes it highly effective for refractory and breakthrough nausea and vomiting by simultaneously blocking several pathways involved in emesis.*

Q10:

In the context of cardio-oncology, which of the following statements regarding trastuzumab-induced cardiotoxicity is correct?
a) It is dose-dependent and irreversible, similar to anthracyclines.
b) It is unrelated to HER2 signalling inhibition in the heart.
c) It is often reversible upon drug cessation and is not dose-dependent.
d) It primarily manifests as QTc prolongation and arrhythmias.

Answer:

c) It is often reversible upon drug cessation and is not dose-dependent.
*Rationale: Trastuzumab causes Type II cardiotoxicity. It is not dose-dependent and is related to the blockade of HER2 signalling, which is important for cardiomyocyte survival and repair. The dysfunction (reduced LVEF) is often reversible upon holding the drug and initiating heart failure medications (ACE inhibitors, beta-blockers).*

Section 2: Extended Matching Questions (EMQ) Set

Theme: Oncology Toxicities - Prevention, Management, and Key Agents

Options:
A) Febrile Neutropenia
B) Cisplatin-Induced Nephrotoxicity
C) Irinotecan-Induced Delayed Diarrhoea
D) Anthracycline-Induced Cardiotoxicity (Type I)
E) Trastuzumab-Induced Cardiotoxicity (Type II)
F) Immune-Related Colitis (from ICIs)
G) Peripheral Sensory Neuropathy
H) Hemorrhagic Cystitis (from Ifosfamide)
I) Palmar-Plantar Erythrodysesthesia (PPE)
J) Extravasation of a Vesicant

For each description below, select the SINGLE MOST APPROPRIATE toxicity from the list above.

1)

A toxicity characterised by a cumulative, dose-dependent decline in left ventricular ejection fraction (LVEF), mediated by oxidative stress and often irreversible.

Answer:

D) Anthracycline-Induced Cardiotoxicity (Type I)
Rationale: This defines Type I cardiotoxicity, typical of anthracyclines like doxorubicin. The risk is directly related to cumulative dose, and the damage to cardiomyocytes is often permanent, leading to strict lifetime dose limits.

2)

An oncologic emergency requiring immediate hospitalisation for IV antibiotics; typically presents with fever during the neutrophil nadir period post-chemotherapy.

Answer:

A) Febrile Neutropenia
*Rationale: Fever (≥38.0°C) in a patient with neutropenia (ANC <0.5 x 10⁹/L or expected) is a medical emergency due to the high risk of rapid progression to life-threatening sepsis. Empiric broad-spectrum IV antibiotics must be given within 1 hour.*

3)

A toxicity managed by holding the causative drug and initiating high-dose corticosteroids, with a slow taper over at least 4 weeks to prevent rebound inflammation.

Answer:

F) Immune-Related Colitis (from ICIs)
Rationale: This is the standard management for moderate-to-severe immune-related adverse events (irAEs) like colitis. The inflammation is driven by an unchecked immune response, requiring immunosuppression with corticosteroids. Rapid tapers can lead to recurrence.

4)

Prevented by aggressive pre- and post-hydration with normal saline to maintain high urine output and minimise drug concentration in renal tubules.

Answer:

B) Cisplatin-Induced Nephrotoxicity
Rationale: Hydration is the cornerstone of preventing cisplatin nephrotoxicity. The goal is to dilute the concentration of cisplatin in the renal tubules, where it causes direct tubular cell damage.

5)

A toxicity where the specific antidote dexrazoxane may be used following tissue infiltration to limit tissue damage.

Answer:

J) Extravasation of a Vesicant
Rationale: Dexrazoxane is a topoisomerase II inhibitor that is specifically indicated as an antidote for anthracycline (e.g., doxorubicin) extravasation. It is given IV over 3 consecutive days to reduce the risk of severe tissue necrosis.

6)

Characterised by a 'glove and stocking' distribution of tingling and numbness, often cumulative and dose-limiting with agents like oxaliplatin and paclitaxel.

Answer:

G) Peripheral Sensory Neuropathy
Rationale: This is the classic description of chemotherapy-induced peripheral neuropathy (CIPN). It starts symmetrically in the distal extremities and can progress, affecting function and quality of life, often necessitating dose reductions.

7)

Prevented by the concurrent administration of Mesna, which binds and inactivates a toxic metabolite in the urine.

Answer:

H) Hemorrhagic Cystitis (from Ifosfamide)
*Rationale: The ifosfamide metabolite acrolein is urotoxic. Mesna (sodium 2-mercaptoethanesulfonate) is given to provide free thiol groups that bind acrolein in the urine, preventing it from damaging the bladder mucosa.*

8)

Managed with a high-dose loperamide regimen (e.g., 4 mg stat, then 2 mg every 2 hours) and close monitoring for dehydration.

Answer:

C) Irinotecan-Induced Delayed Diarrhoea
Rationale: Delayed diarrhoea post-irinotecan is a secretory diarrhoea that can be severe and life-threatening. An aggressive loperamide regimen is the standard first-line intervention to control fluid loss.

9)

A reversible reduction in LVEF that is not dose-dependent and is related to the blockade of a specific growth factor receptor.

Answer:

E) Trastuzumab-Induced Cardiotoxicity (Type II)
*Rationale: Trastuzumab targets HER2. Blocking this receptor in cardiomyocytes, which rely on HER2 for stress response and repair, can lead to reversible systolic dysfunction. This contrasts with the irreversible, dose-dependent damage of anthracyclines.*

10)

A cutaneous toxicity presenting as painful erythema and desquamation on palms and soles, commonly associated with fluoropyrimidines like capecitabine.

Answer:

I) Palmar-Plantar Erythrodysesthesia (PPE)
Rationale: Also called Hand-Foot Syndrome, PPE is a well-known toxicity of fluoropyrimidines, certain TKIs, and liposomal doxorubicin. It is thought to result from capillary leakage of drug in areas of friction and pressure.

Section 3: Integrated Long Answer Clinical Scenario

Scenario: Mrs. Eleanor Green, a 58-year-old woman, is starting adjuvant chemotherapy for Stage III colon cancer. Her regimen is FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil bolus + 46-hour infusion). She has a history of well-controlled hypertension (amlodipine 5mg daily) and mild osteoarthritis.

Q: As the oncology pharmacist, you are conducting pre-treatment education and planning supportive care.
1. Outline your counselling points regarding the prevention and management of the TWO most dose-limiting toxicities specific to the components of her FOLFOX regimen.
2. Detail the antiemetic prophylaxis regimen you would recommend for her, explaining the rationale for each drug component.
3. Mrs. Green calls the day after her first treatment complaining of severe, watery diarrhoea (8 episodes in 12 hours). Describe your assessment and management plan for this acute situation.
4. Considering her history, what specific cardio-oncology consideration is important before and during her treatment?

In-depth Answer:

1. COUNSELLING ON DOSE-LIMITING TOXICITIES:

  • Toxicity 1: Oxaliplatin-Induced Peripheral Neuropathy

    • Prevention: Counsel on cold avoidance during and for several days after the infusion. This includes: Do not drink cold beverages, use gloves when handling items from the fridge/freezer, wear a scarf over the face in cold/windy weather, avoid cold metal surfaces. This prevents exacerbation of acute cold-induced neuropathy.

    • Management: Instruct her to report any tingling, numbness, or pain in her fingers/toes, or difficulty with buttons or walking. Explain that neuropathy may be cumulative. Early reporting allows for potential dose adjustments to prevent permanent, disabling toxicity.

  • Toxicity 2: 5-Fluorouracil-Induced Mucositis & Diarrhoea

    • Prevention for Mucositis: For the 46-hour infusion, advise oral cryotherapy (sucking ice chips) for 30 minutes starting 5 minutes before the 5-FU bolus and continuing during the bolus. This causes vasoconstriction, reducing blood flow and drug delivery to the oral mucosa, significantly lowering the risk and severity of oral mucositis.

    • Management Plan for Diarrhoea: Provide a clear, written plan. Instruct her to:

      1. Start loperamide 4 mg at the first sign of loose stools.

      2. Then take 2 mg every 2 hours until she has been stool-free for 12 hours.

      3. Increase fluid intake (water, broth) to prevent dehydration.

      4. Contact the oncology unit immediately if she has >6-8 stools per day, fever, dizziness, or severe cramping, as this may indicate need for hospitalisation and IV fluids/octreotide.

2. ANTIEMETIC PROPHYLAXIS REGIMEN & RATIONALE:

  • Regimen:

    • Day 1 (Chemotherapy Day): Palonosetron 0.25 mg IV + Dexamethasone 8 mg IV + Aprepitant 125 mg orally.

    • Days 2 & 3: Aprepitant 80 mg orally daily + Dexamethasone 8 mg orally daily.

    • Supply: Metoclopramide 10 mg or Olanzapine 2.5-5 mg as a rescue/breakthrough prescription.

  • Rationale:

    • FOLFOX has moderate emetogenic risk. A three-drug regimen (NK1 + 5-HT3 + steroid) is recommended for optimal control.

    • Palonosetron: A second-generation 5-HT3 antagonist with a longer half-life and higher affinity, effective for acute CINV.

    • Dexamethasone: A potent corticosteroid that synergises with other antiemetics. Given for 3 days to cover both acute and delayed phases.

    • Aprepitant: An NK1 receptor antagonist crucial for preventing delayed nausea and vomiting (days 2-5).

    • Rescue Medication: Provided in case of breakthrough symptoms despite prophylaxis.

3. MANAGEMENT OF SEVERE DIARRHOEA:

  • Assessment: This is an urgent clinical situation. Immediate assessment should determine:

    • Stool frequency/character: >8 episodes/24h is severe (Grade 3).

    • Signs of dehydration/toxicity: Dizziness, lightheadedness, reduced urine output, fever.

    • Timing: Post-FOLFOX diarrhoea could be from 5-FU (mucosal injury) or potentially an infection.

  • Management Plan:

    1. Immediate Action: Instruct her to go to the hospital Emergency Department or the Acute Oncology Service. Severe chemotherapy-induced diarrhoea requires prompt medical assessment.

    2. Hospital Management Expected:

      • IV Hydration & Electrolyte Replacement: To correct dehydration and imbalances.

      • Escalated Antidiarrheal Therapy: May switch to subcutaneous octreotide if high-dose loperamide is insufficient.

      • Infection Work-up: Stool cultures to rule out C. difficile or other infections.

      • Dose Modification: Subsequent cycles will likely require a dose reduction of 5-FU to prevent recurrence.

4. CARDIO-ONCOLOGY CONSIDERATION:

  • Pre-Treatment Assessment: Given her history of hypertension, it is crucial to ensure her blood pressure is well-controlled before starting chemotherapy. 5-FU is associated with coronary vasospasm (which can present as chest pain), and pre-existing hypertension is a risk factor for cardiovascular complications.

  • Ongoing Monitoring & Management:

    • Blood Pressure Monitoring: Advise her to monitor her BP at home during treatment and report any significant elevations or symptoms like chest pain, palpitations, or shortness of breath immediately.

    • Medication Review: Confirm her amlodipine is appropriate and effective. Caution should be exercised with other potential agents: Avoid fluoroquinolone antibiotics (e.g., ciprofloxacin) if she needs treatment for an infection, as they can prolong QTc and have other interactions.

    • Patient Education: Counsel her to report any new or worsening chest pain, pressure, or breathlessness during or after the infusion, as this could indicate 5-FU-induced angina, requiring immediate cessation of the infusion and cardiac evaluation.